{
    "clinical_study": {
        "@rank": "50533", 
        "brief_summary": {
            "textblock": "This is a study to determine whether testosterone replacement with TheraDerm can improve\n      bone density, mood, sex drive, thinking, and distribution of body fat and muscle mass in\n      women with hypopituitarism."
        }, 
        "brief_title": "Androgen Replacement Therapy in Women With Hypopituitarism", 
        "completion_date": "August 2004", 
        "condition": "Hypopituitarism", 
        "condition_browse": {
            "mesh_term": "Hypopituitarism"
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomized into 2 groups to receive testosterone replacement therapy or\n      placebo. Group 1 will receive 2 testosterone patches and estrogen pills for 12 months. Group\n      2 will receive 2 placebo patches and estrogen pills for 12 months. Changes in bone density,\n      bone metabolism markers, body composition, libido, and quality of life will be compared in\n      the women receiving testosterone replacement therapy with that of the women receiving\n      placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Hypogonadism and/or hypoadrenalism of central origin\n\n          -  Testosterone or free testosterone level below the median for age-matched normal\n             controls\n\n          -  Prior estrogen preparation for at least 6 months\n\n        Exclusion criteria:\n\n          -  Any disease known to affect bone metabolism, including untreated hypothyroidism or\n             hyperthyroidism\n\n          -  Change in thyroid hormone dose in the last 3 months\n\n          -  Untreated Cushing's syndrome\n\n          -  Renal failure\n\n          -  Alcoholism\n\n          -  Anorexia nervosa\n\n          -  Prior use of medication known to affect bone metabolism (e.g., supraphysiologic doses\n             of glucocorticoids, phenytoin, bisphosphonates, or calcitonin) within the past 3\n             months\n\n          -  Pregnant or nursing\n\n          -  Uncontrolled hypertension\n\n          -  ALT greater than 3 times upper limit of normal\n\n          -  Serum creatinine greater than 2 times the upper limit of normal\n\n          -  Any contraindication to estrogen therapy, including history of breast cancer or\n             undiagnosed uterine bleeding\n\n          -  Concurrent growth hormone replacement therapy, if patient has been receiving it for\n             less than 2 years"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "December 5, 2001", 
        "id_info": {
            "nct_id": "NCT00027430", 
            "org_study_id": "FD-R-1981-01", 
            "secondary_id": "FD-R-001981-01"
        }, 
        "intervention": {
            "intervention_name": "TheraDerm", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "contact": {
                "last_name": "Anne Klibanski, M.D.", 
                "phone": "617-726-3870"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Anne Klibanski, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "TheraDerm Administration in Women With Hypopituitarism", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Anne Klibanski, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00027430"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2001"
    }, 
    "geocoordinates": {
        "Massachusetts General Hospital": "42.358 -71.06"
    }
}